Titre :

Paroxysmal nocturnal hemoglobinuria (PNH) and vascular liver disease (VLD): eculizumab therapy decreases mortality, and thrombotic complications.

Auteur(s) :

Plessier, Aurélie [Auteur]
Hôpital Beaujon [AP-HP]
Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)]
Esposito-Farèse, Marina [Auteur]
Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique [CIC 1425]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Baiges, Anna [Auteur]
Shukla, Akash [Auteur]
Garcia Pagan, Juan Carlos [Auteur]
De Raucourt, Emmanuelle [Auteur]
Hôpital Beaujon [AP-HP]
Ollivier-Hourmand, Isabelle [Auteur]
Hôpital Côte de Nacre [CHU Caen]
Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen]
Cervoni, Jean-Paul [Auteur]
Service d'Hépatologie [CHRU Besançon]
De Ledinghen, Victor [Auteur]
Bordeaux Research In Translational Oncology [Bordeaux] [BaRITOn]
Hôpital Haut-Lévêque [CHU Bordeaux]
Tazi, Zoubida [Auteur]
Nousbaum, Jean Baptiste [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Bun, René [Auteur]
Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique [CIC 1425]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Bureau, Christophe [Auteur]
Service de Gastroentérologie et pancréatologie [CHU Toulouse]
Silvain, Christine [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Tournilhac, Olivier [Auteur]
CHU Estaing [Clermont-Ferrand]
Gerfaud-Valentin, Mathieu [Auteur]
Hôpital de la Croix-Rousse [CHU - HCL]
Durand, François [Auteur]
Hôpital Beaujon [AP-HP]
Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)]
Goria, Odile [Auteur]
Service d'Hépato-Gastroentérologie [CHU Rouen]
Tellez, Luis [Auteur]
Albillos, A. [Auteur]
Gioia, S. [Auteur]
Riggio, O. [Auteur]
De Gottardi, A. [Auteur]
Payance, Audrey [Auteur]
Hôpital Beaujon [AP-HP]
Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)]
Rautou, Pierre-Emmanuel [Auteur]
Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)]
Service d’Hépatologie [Hôpital Beaujon]
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Charbonnier, Aude [Auteur]
Institut Paoli-Calmettes [IPC]
Elkrief, Laure [Auteur]
Département d'Hépato-Gastroentérologie [Hôpital Trousseau, Tours]
Peffault De La Tour, Regis [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Valla, Dominique-Charles [Auteur]
Hôpital Beaujon [AP-HP]
Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)]
Gault, Nathalie [Auteur]
Hôpital Beaujon [AP-HP]
Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique [CIC 1425]
Département d'Epidemiologie, Biostatistique et Recherche Clinique [DEBRC]
Sicre De Fontbrune, Flore [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]

Titre de la revue :

American Journal of Hematology

Nom court de la revue :

Am J Hematol

Date de publication :

2022-01-26

ISSN :

1096-8652

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

A total of 2%–10% of patients with vascular liver disease (VLD) have paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab reduces complement-mediated haemolytic activity in PNH. This study was aimed at assessing the impact ...
Lire la suite >A total of 2%–10% of patients with vascular liver disease (VLD) have paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab reduces complement-mediated haemolytic activity in PNH. This study was aimed at assessing the impact of eculizumab on VLD outcome. Retrospective cohort of PNH patients, in Valdig registry, who had VLD diagnosed between 1997 and 2019 is considered. Eculizumab was the exposure of interest. Studied outcomes were death, venous thrombosis, bleeding, arterial ischemic event, infection, and liver-related complications. We compared survival and new thrombotic events from PNH/VLD cohort to Envie2 non-PNH cohort. Sixty-two patients (33 women), median age 35 years (28–48) and median follow-up VLD diagnosis 4.7 years (1.2–9.5), were included. Clone size was 80% (70–90), median hemoglobin concentration was 10.0 g/dl (8–11), and lactate dehydrogenase (LDH) was 736 IU (482–1744). Forty-two patients (68%) had eculizumab; median exposure time was 40.1 [9.3–72.6] months. Mortality was significantly lower in exposed versus nonexposed period: 2.6 versus 8.7 per 100 (PY), incidence rate ratio (IRR) was 0.29, 95% CI (0.1–0.9), p = .035. Thrombosis recurrence occurred less frequently during the exposure to eculizumab: 0.5 versus 2.8 per 100 PY, IRR 0.22 (0.07–0.64). Other secondary end points (i.e., bleeding, arterial ischemic lesions, infection, and liver complications) were less common during the exposure to eculizumab, although not reaching statistical significance. Six-year thrombosis-free survival was 70%, 95% CI [0.60–0.83] for PNH cohort and 83%, 95% CI [0.70–1.00] for non-PNH Envie 2 patients, (p < .001). In conclusion, patients with PNH and VLD are at higher risk of recurrent thrombosis than non-PNH patients. Eculizumab is significantly associated with a lower mortality and less thrombotic recurrence in patients with PNH and VLD.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T02:27:37Z
2024-03-08T13:37:18Z